Mitogen-activated protein kinase is required for bryostatin 1-induced differentiation of the human Acute Lymphoblastic Leukemia cell line Reh

被引:0
作者
Wall, NR [1 ]
Mohammad, RM [1 ]
Al-Katib, AM [1 ]
机构
[1] Wayne State Univ, Sch Med, Div Hematol & Oncol, Dept Internal Med,Karmanos Canc Inst, Detroit, MI 48201 USA
来源
CELL GROWTH & DIFFERENTIATION | 2001年 / 12卷 / 12期
关键词
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Bryostatin I (bryo 1) is known to induce the differentiation and cell cycle arrest of human lymphoid leukemia cells in vitro. The extracellular signal-regulated kinase ERK originally identified as a participant in mitogenic signaling, has recently been implicated in the signaling of cellular differentiation. To examine the role of the ERK/mitogen-activated protein (MAP) kinase pathway in B-lymphoid cell differentiation of the Reh Acute Lymphoblastic Leukemia cell line, the effects of bryo I on ERK activation were determined. On bryo I treatment, the activity of ERK2 (p42) rapidly increased, with ERK1 (p44) protein levels remaining constant. p44/42 immunoprecipitates from lysates of bryo 1-treated cells had increased their ability to phosphorylate the transcription factor Elk-1. Constitutive AP-1 activity was shown to be potentiated after bryo I treatment using electrophoretic mobility shift assays. The protein composition of the AP-1 transcription factor complex activated by bryo I was analyzed using supershift analysis with specific antibodies against c-Fos, Fos B, c-Jun, Jun B, and Jun D proteins. Supershift analysis revealed that the bryo 1-induced AP-1 complex was composed predominantly of Fos B and Jun D. Therefore, we evaluated the effects of inhibiting MAP/ERK kinase (MEK) on both DNA binding and cellular differentiation. Treatment of Reh cells with 20 muM PD98059, a specific inhibitor of MEK, inhibited bryo 1-induced ERK activity and DNA binding. Furthermore, PD98059 blocked the bryo 1-induced differentiation of Reh cells, as assessed by a number of features associated with lymphoid differentiation, including changes in morphology, cell growth arrest, attachment, and increased expression of the leukocyte integrin CD11c. Moreover, transient transfection of Reh cells with antisense MAP kinase oligonucleotides blocked bryo 1-induced expression of CD11c. Our analysis also shows that CD11c's gene promoter activity is augmented by bryo 1. Therefore, we conclude that activation of the MEK/ERK signaling pathway is necessary for bryo 1-induced differentiation of the pre-B Acute Lymphoblastic Leukemia cell line Reh.
引用
收藏
页码:641 / 647
页数:7
相关论文
共 28 条
  • [1] SELECTIVE REQUIREMENT FOR MAP KINASE ACTIVATION IN THYMOCYTE DIFFERENTIATION
    ALBEROLAILA, J
    FORBUSH, KA
    SEGER, R
    KREBS, EG
    PERLMUTTER, RM
    [J]. NATURE, 1995, 373 (6515) : 620 - 623
  • [2] BRYOSTATIN 1-INDUCED MODULATION OF THE ACUTE LYMPHOBLASTIC-LEUKEMIA CELL-LINE REH
    ALKATIB, A
    MOHAMMAD, RM
    KHAN, K
    DAN, ME
    PETTIT, GR
    SENSENBRENNER, LL
    [J]. JOURNAL OF IMMUNOTHERAPY, 1993, 14 (01) : 33 - 42
  • [3] ALKATIB A, 1993, EXP HEMATOL, V21, P61
  • [4] ALKATIB A, 1992, AM J HEMATOL, V40, P264
  • [5] THE ROLE OF JUN, FOS AND THE AP-1 COMPLEX IN CELL-PROLIFERATION AND TRANSFORMATION
    ANGEL, P
    KARIN, M
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1072 (2-3) : 129 - 157
  • [6] JUN-B DIFFERS IN ITS BIOLOGICAL PROPERTIES FROM, AND IS A NEGATIVE REGULATOR OF, C-JUN
    CHIU, R
    ANGEL, P
    KARIN, M
    [J]. CELL, 1989, 59 (06) : 979 - 986
  • [7] HOW MAP KINASES ARE REGULATED
    COBB, MH
    GOLDSMITH, EJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (25) : 14843 - 14846
  • [8] ACTIVATION OF MAP KINASE KINASE IS NECESSARY AND SUFFICIENT FOR PC12 DIFFERENTIATION AND FOR TRANSFORMATION OF NIH 3T3 CELLS
    COWLEY, S
    PATERSON, H
    KEMP, P
    MARSHALL, CJ
    [J]. CELL, 1994, 77 (06) : 841 - 852
  • [9] The MAP kinase pathway controls differentiation from double-negative to double-positive thymocyte
    Crompton, T
    Gilmour, KC
    Owen, MJ
    [J]. CELL, 1996, 86 (02) : 243 - 251
  • [10] Dai Y, 2001, CANCER RES, V61, P5106